Comparing three wearable accelerometers to measure early activity after cardiac surgery

Charles H. Brown IV, MD, MHS, Lisa Yanek, MPH, Ryan Healy, BA, Tiffany Tsay, MPH, Junrui Di, PhD, Lee Goeddel, MD, MPH, Daniel Young, PT, DPT, PhD, Vadim Zipunnikov, PhD, Jennifer Schrack, PhD, MS, and the Cardiac Surgery Mobility Working Group*

ABSTRACT

Objective: Wearable activity monitors can provide detailed data on activity after cardiac surgery and discriminate a patient’s risk for hospital-based outcomes. However, comparative data for different monitoring approaches, as well as predictive ability over clinical characteristics, are lacking. In addition, data on specific thresholds of activity are needed. The objective of this study was to compare 3 wearable activity monitors and 1 observational mobility scale in discriminating risk for 3 hospital-based outcomes, and to establish clinically relevant step thresholds.

Methods: Cardiac surgery patients were enrolled between June 2016 and August 2017 in a cohort study. Postoperative activity was measured by 3 accelerometry monitors (StepWatch Ambulation Monitor, Fitbit Charge HR, and ActiGraph GT9X) and 1 nurse-based observation scale. Monitors represent a spectrum of characteristics, including wear location (ankle/wrist), output (activity counts/steps), consumer accessibility, and cost. Primary outcomes were duration of hospitalization >7 days, discharge to a nonhome location, and 30-day readmission.

Results: Data were available from 193 patients (median age 67 years [interquartile range, 58-72]). All postoperative day 2 activity metrics (ie, from StepWatch, Fitbit, ActiGraph, and the observation scale) were independently associated with prolonged hospitalization and discharge to a nonhome location. Only steps as measured by StepWatch was independently associated with 30-day readmission. Overall, StepWatch provided the greatest discrimination (C-statistics 0.71-0.76 for all outcomes). Step thresholds between 250 and 500 steps/day identified between 74% and 96% of patients with any primary outcome.

Conclusions: Data from wearable accelerometers provide additive value in early postoperative risk-stratification for hospital-based outcomes. These results both support and provide guidance for activity-monitoring programs after cardiac surgery. (JTCVS Open 2022;11:176-91)

From the Departments of *Anesthesiology & Critical Care Medicine and 3Medicine, Johns Hopkins University School of Medicine, Baltimore, Md; Departments of *Epidemiology and 4Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; and *Department of Physical Therapy, University of Nevada, Las Vegas, Las Vegas, Nev.

Funded by a Johns Hopkins inHealth Grant to C.B. (K76AG057020-01).

Present Address of Kaushik Mandal: Department of Surgery, Wayne State University School of Medicine, Detroit, Mich.

Present address of Ryan Healy: Boston University School of Medicine, Boston, Mass.

Present address of Tiffany Tsay: Virginia Commonwealth University School of Medicine, Richmond, Va.

Present address of Junrui Di: Pfizer, Inc, Cambridge, Mass.

* See Appendix 1 for a listing of the Cardiac Surgery Mobility Working Group.

Received for publication Sept 22, 2021; revisions received March 30, 2022; accepted for publication May 23, 2022; available ahead of print June 29, 2022.

Address for reprints: Charles H. Brown, IV, MD, MHS, Department of Anesthesiology & Critical Care Medicine, Johns Hopkins University School of Medicine, Zayed 6208, 1800 Orleans St, Baltimore, MD 21210 (E-mail: cbrownv@jhmi.edu).

2666-2736

Copyright © 2022 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

https://doi.org/10.1016/j.xjon.2022.05.011
Abbreviations and Acronyms

ICU = intensive care unit
IQR = interquartile range
JH-HLM = Johns Hopkins-Highest Level of Mobility
logEuroSCORE = logistic European System for Cardiac Operative Risk Evaluation score
ROC = receiver operating curve

Early ambulation and increased physical activity have long been recognized as important for postoperative recovery, and they are core components of enhanced recovery programs after noncardiac and cardiac surgery. An important part of promoting activity and mobility is accurate and timely patient-level measurement of movement. However, such measurement is difficult in hospital settings, as current measurements are typically limited to observations by staff or patient report, which are often not granular, standardized, or complete. This lack of measurement contributes to what has been characterized an “epidemic of low mobility” in hospitalized patients that may be particularly important for older adults, who are at the greatest risk for impaired mobility and poor functional recovery.

Wearable activity monitors can provide novel and detailed data on activity and mobility after surgery, which could be used to guide clinical care protocols, provide research insights, and display information to patients to increase activity. Scattered reports in noncardiac and cardiac surgical populations at different times of recovery have reported associations of activity and mobility metrics with some postoperative outcomes. However, there are a myriad of monitoring devices that can be used, with varying measurement properties and costs. As an alternative to wearable monitors, structured clinical observations of activity and mobility require no extra hardware but provide less granular measurements. For cardiac surgery programs considering all of these options, comprehensive data comparing different monitoring approaches are needed to understand which monitoring approach provides the most clinically relevant information and to establish thresholds of activity and mobility that can be used to target activity after surgery.

To address these questions, we conducted an observational cohort study after cardiac surgery, with measurement of early activity and mobility using 3 different wearable activity monitors and 1 validated nurse-assessed scale (Johns Hopkins Highest Level of Mobility [JH-HLM] scale). The wearable activity monitors were chosen to represent a spectrum of device characteristics, including wear location (ankle/wrist), type of output (activity counts/step counts), consumer-accessibility, and cost. We hypothesized that measurement of early activity after surgery (ie, postoperative day 2) using wearable accelerometers and/or an observation scale would discriminate risk for hospital-based outcomes (duration of hospitalization, discharge location, and 30-day readmission), even after accounting for other known predictors of these outcomes. We also identified clinically relevant thresholds for number of steps to identify patients at greatest risk for the hospital-based outcomes.

METHODS

The study was approved by the Johns Hopkins Medicine Institutional Review Board (IRB00086547; approved on February 16, 2016). Patients provided written consent at Johns Hopkins in the week before or the day of surgery to be part of a research study, and the consent included distribution of patient information as part of the study.

Study Design, Participants, and Sample Size

This observational cohort study enrolled elective cardiac surgery patients at Johns Hopkins between June 4, 2016, and August 9, 2017. Inclusion criteria were coronary artery bypass graft and/or valve surgery, aortic surgery, and/or myectomy. Exclusion criteria included lung/heart transplant, or planned insertion of a ventricular assist device. Data on a subset of these patients have been published previously.

For sample size determination, we assumed steps of 230 ± 180 and 170 ± 88 in patients discharged to home versus not-home and steps of 510 ± 700 and 220 ± 500 for patients with hospitalization <7 days versus longer, based on previous work. Using these assumptions, a sample size of 176 would provide >80% power for a difference in steps, with significance of $P = .05$.

Activity Measurement

Activity was monitored using 3 devices and 1 nurse observation scale. The devices were (1) StepWatch Activity Monitor (Modus Health), (2) ActiGraph GT9X, and (3) Fitbit Charge HR (Fitbit Inc). Device characteristics are described in Table 1, and all devices can be purchased and are clinically available. For nurse observation, nurses documented the greatest level of mobility observed on their shift using the JH-HLM scale (range, 1-8), with scores 1 to 5 indicating activity that ranges from bed-bound to standing and scores of 6-8 indicating ambulation ≥10 steps, ≥10 feet, and ≥250 feet, respectively. The Fitbit and ActiGraph were placed on the same wrist and the StepWatch was placed on the ankle by 8 AM after surgery. Patients were encouraged to wear devices at all times (except bathing) during hospitalization. Staff visited patients every 1 to 2 days (except weekends) to monitor compliance. For periods of nonwear, staff estimated with patients and nurses the removal time.

Outcome Measurement

Three key outcomes were established before data collection and were duration of hospitalization after surgery, discharge to a nonhome location, and readmission within 30 days of hospital discharge. Duration of hospitalization and discharge location were abstracted from the electronic health record. No patients were institutionalized at baseline. Patients who were discharged to a hotel or with family were considered discharged home. Information on 30-day readmission was abstracted from the health record, which included routine follow-up calls, 1-month clinic appointments, and data from the state health information exchange. Readmission was defined as any overnight stay in a hospital within 30 days of discharge from the initial surgery.
TABLE 1. Characteristics of 3 wearable accelerometers worn by patients

| Monitor               | Manufacturer                | Location of wear | Output          | Availability                  |
|-----------------------|-----------------------------|------------------|-----------------|-------------------------------|
| StepWatch Activity Monitor | StepWatch; Modus Health LLC | Ankle            | Steps           | Available by direct order from vendor website |
| ActiGraph GT9X        | ActiGraph LLC               | Wrist            | Activity counts | Available by direct order from vendor website |
| Fitbit Charge HR      | Fitbit; Fitbit Inc          | Wrist            | Steps           | Easily available to consumers through multiple platforms and the least expensive |

Baseline and Perioperative Covariate Data

Patient information was obtained by direct interview and abstraction from the electronic record. Comorbidities, including the logistic European System for Cardiac Operative Risk Evaluation score (logEuroSCORE), were assessed based on information from the medical record and from patient self-report. The logEuroSCORE was chosen because the included variables in this score were potentially important confounding variables based on literature review. The World Health Organization-Disability Assessment Schedule 2.0 (ie, WHO-DAS 2.0)10 and ability to complete Instrumental Activities of Daily Living were also reported by patients and reflect the time before hospitalization. All patients received a preoperative education packet, as part of usual care, that emphasized the importance of mobility. Clinical protocols targeted out-of-bed to chair on the night of surgery and ambulation 2-3 times daily afterward. Physical and occupational services were available based on nursing screen.

Statistical Analysis

Steps per minute and per day were available from the Fitbit and StepWatch devices, whereas the vector magnitude of activity counts (unitless quantities of movement across 3 axes) per minute and per day were available from the ActiGraph. Activity metrics on postoperative day 2 were the primary exposure because we were interested in early metrics of activity, and this was the first day with 24-hour data. Devices were considered to be worn if activity was registered between placement and removal, with no documented noncompliance.

Patient characteristics were compared between mobility groups using the Student t test, Wilcoxon rank-sum, \( \chi^2 \), or Fisher exact tests. Multivariable regression analyses were used to examine the association of mobility metrics with each outcome, adjusting for potentially confounding variables. Duration of hospitalization was analyzed with linear regression with inverse normal transformation. Two sets of outcome-specific adjusted regression models were used. The first set of models used outcome-specific variables defined a priori by the research team based on literature review, supplemented by variables associated with both activity and specific outcomes. The second set of models included variables that were unique to validated outcome-specific prediction models.11,17 The potentially confounding variables were outcome specific. For duration of hospitalization, the covariates include age, sex, race, logEuroSCORE, bypass time, and intensive care unit (ICU) duration. For discharge location, the covariates include age, sex, race, baseline instrumental activities of daily living, logEuroSCORE, duration of bypass, and ICU duration. For 30-day readmission, the covariates include age, sex, race, baseline instrumental activities of daily living, logEuroSCORE, duration of hospitalization, discharge location, ICU duration, and transfusion of red cell units. Standard model diagnostics were examined to ensure good model fit, including residuals, collinearity and influence measures, and goodness-of-fit tests (Osiris and Rojek test) for logistic models and r-squared values for linear models.

The discrimination of activity metrics was examined using outcome-specific receiver operating curves (ROCs), using C-statistics. Nonstandard ROC curves were used since the outcome of interest was less common as activity increased. Duration of hospitalization was categorized using a cut point of 7-days for the ROC analyses. Youden18 criteria were used to determine step thresholds which maximized sensitivity and specificity. Since ROC curves may be biased when predictor scales are dichotomized or have coarse categorization (JH-HLM) and/or zero values (Fitbit),19 we also used the “fbroc” package in R with 1000 bootstrapped samples.

SAS, version 9.4 and RStudio, version 1.3.959, were used for main analyses. Missingness for nondevice variables was low (<10%) and considered to be missing at random, thus pairwise and listwise deletion methods were performed. We calculated the proportion of device missingness as the number of patients who wore the device for any portion of day 2 divided by the total number of patients (\( n = 193 \)). We calculated the proportion of device data missingness as the number of patients with complete data for every minute in postoperative day 2 divided by the number of patients who wore the device for any portion of day 2. Missing minute-level device data were imputed to zero (no movement).

RESULTS

Perioperative and Activity Characteristics

Data were available from 193 patients, with a median age of 67 years (interquartile range [IQR], 58-72). All patients underwent cardiopulmonary bypass with sternotomy during surgery. In total, 47% were inpatients. A patient flow diagram is shown in Figure E1. Patients with low perioperative mobility tended to be women, with lower functional status, greater logEuroSCORE, and longer intubation and intensive care unit duration (Table 2).

The median duration of hospitalization was 7 days (range, 4-48). Overall, 24 (12%) patients were discharged to a nonhome location, and 34 (18%) patients were readmitted within 30 days. All patients (\( n = 193 \)) had data on duration of hospitalization and discharge location. Five patients were censored for the 30-day readmission outcome because of inadequate postdischarge records. Patient characteristics by each outcome are presented in Tables E1-E3. Patients at risk for all outcomes were older, had greater logEuroSCORE, and longer intensive care unit duration.

Activity on postoperative day 2 was the primary metric of “early activity,” since this information is obtained early enough after surgery to be clinically actionable. On postoperative day 2, 98% (\( n = 189 \)) of patients were wearing at least 1 activity monitor, with 85% (\( n = 164 \)) wearing all 3 monitors; 96% (185/193) wore the StepWatch, 92% (178/193) wore...
### TABLE 2. Patient and perioperative characteristics

| Characteristic                          | Overall (n = 193) | Low mobility* (n = 92) | High mobility* (n = 93) | P value |
|-----------------------------------------|-------------------|------------------------|-------------------------|---------|
| Age, y, median [IQR]                    | 67 [58-72]        | 67.5 [61-73]           | 64 [56-72]              | .18     |
| Male, no. (%)                           | 158 (81.87)       | 68 (73.91)             | 83 (89.25)              | .007    |
| White, no. (%)                          | 147 (76.17)       | 65 (70.65)             | 74 (79.57)              | .16     |
| Living with someone (spouse, family, other), no. (%) (n = 190) | 146 (76.84)       | 77 (84.62)             | 62 (68.13)              | .009    |
| Body mass index, kg/m², median [IQR]    | 28.3 [24.8-32.1]  | 27.4 [23.97-31.64]     | 28.62 [24.98-32.09]     | .43     |
| IADL score, y median [IQR], (n = 189)   | 14 [14-14]        | 14 [14-14]             | 14 [14-14]              | .05     |
| WHO-DAS 2.0 score, z median [IQR], (n = 186) | 4 [2-8]           | 5 [2-10]               | 3 [1-6]                 | .004    |
| Difficulty walking long distances       |                   |                        |                         | .036    |
| No difficulty, no. (%)                  | 82 (43.62)        | 30 (33.33)             | 49 (54.44)              |         |
| Mild difficulty, no. (%)                | 15 (7.98)         | 8 (8.89)               | 7 (7.78)                |         |
| Moderate difficulty, no. (%)            | 20 (10.64)        | 12 (13.33)             | 6 (6.67)                |         |
| Severe difficulty, no. (%)              | 22 (11.7)         | 10 (11.11)             | 11 (12.22)              |         |
| Extreme difficulty or cannot do, no. (%)| 49 (26.06)        | 30 (33.33)             | 17 (18.89)              |         |
| Logistic EuroSCORE                      | 2.9 [1.9-5.1]     | 3.15 [2.1-6.995]       | 2.69 [1.66-4.1]         | .02     |
| Comorbidities                           |                   |                        |                         |         |
| Previous stroke or TIA, no. (%)         | 19 (9.84)         | 10 (10.87)             | 8 (8.6)                 | .60     |
| Depression, no. (%)                     | 20 (10.36)        | 12 (13.04)             | 7 (7.53)                | .22     |
| Hypertension, no. (%)                   | 158 (81.87)       | 78 (84.78)             | 74 (79.57)              | .35     |
| Congestive heart failure, no. (%)       | 72 (37.31)        | 41 (44.57)             | 29 (31.18)              | .06     |
| Peripheral vascular disease, no. (%)    | 25 (12.95)        | 12 (13.04)             | 11 (11.83)              | .80     |
| Diabetes, no. (%)                       | 74 (38.34)        | 39 (42.39)             | 33 (35.48)              | .34     |
| Previous tobacco use, no. (%)           | 109 (56.48)       | 54 (58.7)              | 49 (52.69)              | .41     |
| COPD, no. (%)                           | 26 (13.47)        | 16 (17.39)             | 10 (10.75)              | .19     |
| eGFR, mL/min, mean (SD)                 | 74.31 ± 21.9      | 71.67 ± 24.1           | 76.62 ± 19.5            | .05     |
| Active alcohol and/or drug use, no. (%)  | 28 (14.51)        | 10 (10.87)             | 17 (18.28)              | .15     |
| Mediations                              |                   |                        |                         |         |
| Aspirin, no. (%)                        | 151 (78.24)       | 73 (79.35)             | 72 (77.42)              | .75     |
| Platelet aggregation inhibitor, no. (%) | 40 (20.73)        | 26 (28.26)             | 13 (13.98)              | .02     |
| Beta blocker, no. (%)                   | 137 (70.98)       | 67 (72.83)             | 64 (68.82)              | .55     |
| Calcium channel blocker, no. (%)        | 58 (30.05)        | 24 (26.09)             | 30 (32.26)              | .36     |
| ACE or ARB, no. (%)                     | 94 (48.70)        | 41 (44.57)             | 51 (54.84)              | .16     |
| Any anticoagulant (heparin, coumadin, other), no. (%) | 81 (41.97) | 50 (54.35) | 2 (2.15) | .003 |
| Statin, no. (%)                         | 148 (76.68)       | 74 (80.43)             | 30 (32.26)              | .18     |
| Surgery type                            |                   |                        |                         |         |
| Isolated CAB, no. (%)                   | 111 (57.51)       | 57 (61.96)             | 48 (51.61)              | .18     |
| Isolated valve, no. (%)                 | 49 (25.39)        | 18 (19.57)             | 30 (32.26)              |         |
| CAB + valve, no. (%)                    | 22 (11.40)        | 13 (14.13)             | 9 (9.68)                |         |
| Other, no. (%)                          | 11 (5.70)         | 4 (4.35)               | 6 (6.45)                |         |
| Intraoperative intra-aortic balloon pump, no. (%) | 26 (13.47) | 21 (22.83) | 4 (4.3) | <.001 |
| Hemoglobin, g/dL, median [IQR]          | 9.3 [8.4-10.4]    | 8.7 [7.9-9.6]          | 9.8 [8.8-10.9]          | <.001   |
| Duration of bypass, min, median [IQR]   | 104 [77-139]      | 114 [77-151]           | 104 [77-134]            | .41     |
| Intraoperative red blood cell transfusion, units, median [IQR] | 0 [0-1] | 0 [0-3] | 0 [0-0] | .002 |
| Duration of intubation, h, median [IQR] | 5.3 [3.7-8.8]    | 7.25 [4.58-13.5]       | 4.25 [3.25-6]           | <.001   |
| Duration of ICU stay, h, median [IQR]   | 28.8 [21.8-69.5]  | 50.625 [26.25-93]      | 23 [20.25-45]           | <.001   |
| Duration of hospital stay before surgery, h, median [IQR] | 0 [0-4] | 1.5 [0-4.5] | 0 [0-3] | .07 |

*Low and high mobility are defined based on the median number of steps (as measured by the StepWatch Activity Monitor) on postoperative day 2. StepWatch data was available on 185 patients. **IADL scores range from 0 to 14, with a lower number indicating more difficulty with IADLs. IQR, Interquartile range; IADL, Instrumental Activities of Daily Living; WHO-DAS 2.0, World Health Organization Disability Assessment Schedule 2.0 (12-item); EuroSCORE, European System for Cardiac Operative Risk Evaluation score; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAB, coronary artery bypass; ICU, intensive care unit.*Low and high mobility are defined based on the median number of steps (as measured by the StepWatch Activity Monitor) on postoperative day 2. StepWatch data was available on 185 patients. IADL scores range from 0 to 14, with a lower number indicating more difficulty with IADLs. WHO-DAS 2.0 scores range from 0 to 48, with greater scores indicating greater impairment.
the Fitbit, and 93% (179/193) wore the ActiGraph. On postoperative day 2, of those who wore the StepWatch 96% (179/185) had data for every minute; for Fitbit, 95% (169/178) had data for every minute, and for ActiGraph, 97% (173/179) had data for every minute. The missing minute data for these patients (n = 9) was often overnight when limited mobility was expected. The median value of activity on postoperative day 2 for each monitor was the following: StepWatch 254 steps (IQR, 62-522) (n = 185), Fitbit 37.5 steps (IQR 0-239) (n = 178), and ActiGraph 392,020 counts (IQR, 173,465-591,368) (n = 179). The median JH-HLM score was 7 (IQR 7-8) (n = 193). Mobility generally increased from postoperative days 2-5 (Figure 1), after which healthier patients were discharged, so the average mobility for remaining patients decreased through day 10.

**Association of Activity Metrics on Postoperative Day 2 and Patient Outcomes**

For duration of hospitalization, all metrics of activity on postoperative day 2 were higher in patients who were discharged in <7 days compared with longer (Figure 2). As an example, the median number of StepWatch steps on postoperative day 2 was 424 in patients who were discharged in <7 days, but was 90 in patients with longer hospitalization. All metrics of postoperative day 2 activity (from each approach to activity monitoring) were significantly
associated with prolonged hospitalization in both unadjusted and 2 adjusted models, including an adjusted model based on validated prediction scores using clinical characteristics (Table 3).

Similarly, for discharge location, all metrics of activity on postoperative day 2 were greater in patients who were discharged home compared with a nonhome location (Figure 2). The median number of StepWatch steps on postoperative day 2 was 298 in patients who were discharged home, but was 14.5 in patients who were discharged to a nonhome location. In regression models, there was a strong association of all metrics of activity on postoperative day 2 with discharge to a nonhome location in both unadjusted and 2 adjusted models, including an adjusted model based on validated prediction scores using clinical characteristics (Table 3).

However, for 30-day readmission, the results were mixed. In unadjusted models, there were associations between metrics of activity on postoperative day 2 from 3 measurement tools (StepWatch, ActiGraph, and JH-HLM, but not Fitbit) and 30-day readmission. In adjusted models, only steps as measured by StepWatch on postoperative day 2 was independently associated with 30-day readmission (Figure 2 and Table 3).

As post-hoc sensitivity analyses, we examined metrics of mobility on postoperative day 3. The inferences were unchanged for all unadjusted and adjusted models, except the JH-HLM score on postoperative day 3 was newly
TABLE 3. Associations of postoperative day 2 activity with duration of hospitalization, discharge to a nonhome location, and 30-day readmission

| Duration of hospitalization (β-coefficient) | Unadjusted model | Adjusted model #1 (covariates prespecified)* | Adjusted model #2 (covariates from validated risk models)|
|-------------------------------------------|------------------|---------------------------------------------|---------------------------------------------|
|                                           | β-coefficient or EuroSCORE (95% CI) | β-coefficient or physical (95% CI) | β-coefficient or OR (95% CI) |
| StepWatch, per 100 steps                   | −0.14 (−0.18, −0.11) | <.001 | −0.08 (−0.12, −0.05) | <.001 |
| Fitbit, per 100 steps                      | −0.09 (−0.13, −0.05) | <.001 | −0.06 (−0.09, −0.03) | <.001 |
| ActiGraph, per 50,000 counts               | −0.06 (−0.08, −0.04) | <.001 | −0.03 (−0.05, −0.01) | .003  |
| JH-HLM#                                   | −0.25 (−0.31, −0.18) | <.001 | −0.14 (−0.20, −0.08) | <.001 |

Discharge to a nonhome location vs home location (OR)

|                                            | Unadjusted model | Adjusted model #1 (covariates prespecified)* | Adjusted model #2 (covariates from validated risk models)|
|-------------------------------------------|------------------|---------------------------------------------|---------------------------------------------|
|                                           | β-coefficient or EuroSCORE (95% CI) | β-coefficient or physical (95% CI) | β-coefficient or OR (95% CI) |
| StepWatch, per 100 steps                   | 0.55 (0.40-0.76)  | <.001 | 0.57 (0.41-0.80)  | .001 |
| Fitbit, per 100 steps                      | 0.63 (0.40-0.98)  | .04   | 0.60 (0.36-0.99)  | .04  |
| ActiGraph, per 50,000 counts               | 0.76 (0.65-0.89)  | <.001 | 0.74 (0.59-0.92)  | .007 |
| JH-HLM#                                   | 0.65 (0.54-0.78)  | <.001 | 0.69 (0.55-0.87)  | .002 |

30-d readmission vs no 30-d readmission (OR)

|                                            | Unadjusted model | Adjusted model #1 (covariates prespecified)* | Adjusted model #2 (covariates from validated risk models)|
|-------------------------------------------|------------------|---------------------------------------------|---------------------------------------------|
|                                           | β-coefficient or EuroSCORE (95% CI) | β-coefficient or physical (95% CI) | β-coefficient or OR (95% CI) |
| StepWatch, per 100 steps                   | 0.71 (0.59-0.87)  | .006 | 0.8 (0.65-1.00)   | .05  |
| Fitbit, per 100 steps                      | 0.91 (0.78-1.06)  | .23  | 1.00 (0.86-1.17)  | .98  |
| ActiGraph, per 50,000 counts               | 0.98 (0.97-1.00)  | .03  | 0.99 (0.97-1.01)  | .29  |
| JH-HLM#                                   | 0.79 (0.67-0.93)  | .005 | 0.92 (0.72-1.17)  | .51  |

Comparison of Different Methods of Measuring Postoperative Activity

To compare each approach to activity monitoring, outcome-specific ROCs are shown in Figure 3. Taken as a whole, StepWatch provided the highest discrimination (C-statistics 0.71-0.76 for all outcomes). For both duration of hospitalization and 30-day readmission, the greatest discrimination was obtained using steps as derived from StepWatch (C-statistic for hospitalization >7 days 0.74 for StepWatch vs 0.52-0.69 for other metrics, and C-statistic for 30-day readmission 0.71 for StepWatch vs 0.47-0.63 for

associated with 30-day readmission in one adjusted model. We separately examined whether the addition of complications, baseline difficulty with walking long distances, or inpatient status would change the inferences as compared to the pre-specified adjusted models. The inferences were generally unchanged, with the following exceptions. For StepWatch, the addition of baseline difficulty with walking long distances attenuated the adjusted models with 30-day readmission as an outcome. For Fitbit, the addition of inpatient status attenuated one adjusted model with discharge location as an outcome.
other metrics). For discharge location, discrimination was similar for all methods of monitoring activity (C-statistics 0.73-0.78), except for Fitbit (C-statistic 0.60). In a sensitivity analysis of alternate approaches to calculate C-statistics to account for coarse categorizations (JH-HLM scale) and numerous zero values (Fitbit), the C-statistics for StepWatch and ActiGraph were similar, but those for Fitbit and JH-HLM increased slightly (Table E4).
Clinical Relevant Thresholds of Steps

Because the StepWatch had the best discrimination and the output of the StepWatch is easily interpretable (eg, steps), a range of StepWatch step thresholds with associated sensitivities and specificities for each outcome were calculated (Table 4). As shown, ambulating for <500 steps on postoperative day 2 (highest quartile) identified approximately 87% to 96% of patients who would eventually have hospitalization >7 days, discharge to a nonhome location, or 30-day readmission, although specificities ranged from approximately 29% to 35%. Using a lower cutoff of <250 steps on postoperative day 2 (median value), 74% to 83% of patients with these eventual outcomes would have been identified, with specificities of 56% to 68%. Overall, step thresholds between 250 and 500 steps/day identified between 74% to 96% of patients with any of the three primary outcomes. The number of steps that maximized sensitivity and specificity for hospitalization >7 days was 217 steps (sensitivity 71%, specificity 74%), for discharge to a nonhome location was 147 steps (sensitivity 83%, specificity 70%), and for 30-day readmission was 159 steps (sensitivity 71%, specificity 70%).

DISCUSSION

Decreased physical activity on postoperative day 2 after cardiac surgery, as measured by several types of wearable activity monitors and a nurse-assessed observation scale, was strongly and independently associated with longer duration of hospitalization and discharge to a nonhome location. For 30-day readmission, only steps as measured by StepWatch was independently associated with this outcome, and the strength of the association was less than for other outcomes. Compared with other approaches to monitoring mobility, steps as measured by StepWatch had the greatest discrimination for duration of hospitalization and 30-day readmission. Steps below a range of 250 to 500 steps on postoperative day 2 had sensitivities between 74% and 96% to identify patients at risk for these 3 outcomes (Figure 4). Taken as a whole, these results support the importance of monitoring activity and mobility after cardiac surgery and provide guidance on optimal monitoring methods and clinically relevant thresholds of steps to identify at-risk patients.

Many patients, especially older adults, experience profoundly low levels of activity and mobility during hospitalization and after surgery, even though activity and mobility in the hospital is well established as important for improving patient outcomes, including delirium-prevention and maintaining function. Indeed, activity and mobility are core components of enhanced recovery programs after noncardiac and cardiac surgery. Accurate and efficient measurement of activity and mobility is critical, but there is no consensus or mandate for measurement. A primary and important result of this study is that, regardless of how activity is measured (ie, lower vs upper extremity, granular vs coarse measurement), low physical activity early after surgery is consistently associated with longer duration of hospitalization and discharge to a nonhome location, and to a lesser extent 30-day readmission—results that are similar to those reported in a broad range of hospitalized patient populations. These associations are independent of other important clinical variables from several outcome-specific prediction models; thus, activity and mobility data appear to provide important additive information to clinical characteristics. Notably, in this study, activity and mobility data were obtained early after surgery, which is a more clinically relevant time than later in a hospitalization. In addition, there is substantial evidence in both medical and surgical patients that in-hospital activity and mobility interventions can improve outcomes for hospitalized patients, including reducing costs and use. These programs may be particularly important for older adults, who often have reduced physical reserve.

Our results also demonstrate that the accuracy of measuring patient activity varies between devices, each of which has different properties. This information is important for clinicians who are considering different approaches to measure activity and mobility. The StepWatch monitor is worn on the ankle and validated for slow gait speed, which is important in patients using a walker or mobility aid. The research-grade ActiGraph is sensitive to upper-extremity movement and reflects activity beyond ambulation, such as in-bed movement. The Fitbit Charge HR is easily available to consumers and relatively low-cost, so could be worn before or after hospitalization to obtain longitudinal data.
By using several different devices in the same patients, the independent and additive information from each device could be compared. Taken as a whole, StepWatch had the best discrimination, and these results highlight the importance of ambulation (since the output of StepWatch is an accurate measure of steps), which likely reflects both patient reserve and ongoing recovery and is an important metric of physical function in older adults. Interestingly, we observed that all metrics of "steps" from wearable activity monitors are not the same. Although both StepWatch and Fitbit report step counts, the outputs were substantially different, with the median steps reported by StepWatch being >5-fold greater than that reported by Fitbit, even in the same patients. The measurement characteristics of StepWatch (ankle-worn, an algorithm validated in low mobility patients) appear to provide greater discrimination with respect to important outcomes. Clinical scales based on nurse observations are low-cost and easily understandable, but are limited by the need for direct observation, documentation burden, and coarse categorization, which do not assess the full range of activity. Our results suggest that JH-HLM scores were independently associated with duration of hospitalization and discharge location, but not 30-day readmission, and performance on ROC curves were slightly worse for JH-HLM compared with StepWatch.

A significant impediment to improving mobility in hospitalized patients after surgery is lack of consensus on an optimal “dose” of mobility. Our data suggest that thresholds in a range of 250 to 500 steps/day on postoperative day 2 after cardiac surgery have sensitivities between 74% and 96% for all outcomes. However, within this range, the specific thresholds that maximize sensitivity and specificity do vary by outcome. The goal of measuring activity also needs to be considered. For instance, to target resources to all patients at high risk for an outcome (such as 30-day readmission), sensitivity needs to be maximized, at the risk of losing specificity. Since there was overlap in the distribution of steps by outcomes, any threshold will need to balance these concerns. Regardless, our finding that <250 to 500 steps/day is associated with adverse outcomes provides an important threshold that should be validated in other patient populations.

Strengths of this study include the use of 3 separate monitors and an observation scale, a large sample, rigorous consideration of confounding variables, a generalizable cardiac surgery population, and clinically relevant outcomes. There are several limitations to consider. First, although staff frequently assessed device wear, compliance was not verified during every minute, and mobility may be underestimated. Second, as with all observational studies, there is a potential for residual confounding or model overfitting. It also remains unclear if intervening on mobility could improve outcomes. Third, although all monitoring devices are commercially available for medical purchase, there are differences in patient-availability, cost, and ease of data output for the 3 monitors, which may limit the use of some devices. Incorporating monitoring devices into a clinical workflow could also be challenging.

FIGURE 4. Physical activity and mobility were measured after cardiac surgery using wearable accelerometry devices. Steps on postoperative day 2 were lower in patients with 3 adverse hospital outcomes, with 250 to 500 steps/day appearing to be an important cutoff.
Data from wearable accelerometry monitors early after cardiac surgery provide additive value in identifying patients at risk for prolonged hospitalization, discharge to a nonhome location, and 30-day readmission, and 250 to 500 steps on postoperative day 2 may be a clinically relevant threshold. However, this study is limited because it is observational and incorporating monitoring devices into a clinical workflow could be challenging. Further studies are needed to examine these cutoffs in other populations and to translate this information into individualized mobility-improvement programs.

Conflict of Interest Statement
C.B. has consulted for and received grant funding from Medtronic. J.D. reports being a doctoral student at the Johns Hopkins University while working on this paper and is now a Pfizer employee, and he has stock or stock options in Pfizer. D.Y. has a grant from the National Institutes of Health unrelated to this study. J.S. has a grant from the National Institutes of Health (paid to Johns Hopkins). All other authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

The authors are grateful for the support of the Clinical Research Core within the Johns Hopkins Department of Anesthesiology & Critical Care Medicine and funding from the Johns Hopkins In-Health initiative.

References

1. Dock W. The evil sequelae of complete bed rest. JAMA. 1944;125:1083-5.
2. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152:292-8.
3. Baxter R, Squiers J, Conner W, Kent M, Fann J, Lodibell K, et al. Enhanced recovery after surgery: a narrative review of its application in cardiac surgery. Ann Thorac Surg. 2020;109:1937-44.
4. Greysen HM, Greysen SR. Mobility assessment in the hospital: what are the "next steps"? J Hosp Med. 2017;12:477-8.
5. Wald HL, Ramsawany R, Perskin MH, Roberts L, Bogaisky M, Suen W, et al. The case for mobility assessment in hospitalized older adults: American geriatrics society white paper executive summary. J Am Geriatr Soc. 2019;67:11-6.
6. Brown CJ, Redden DT, Flood KL, Allman RM. The underrecognized epidemic of low mobility during hospitalization of older adults. J Am Geriatr Soc. 2009;57:1660-5.
7. Agostini PJ, Naidu B, Rajesh P, Stuyn R, Bishay E, Kalkat M, et al. Potentially modifiable factors contribute to limitation in physical activity following thoracotomy and lung resection: a prospective observational study. J Cardiothorac Vasc Anesth. 2014;9:128.
8. Daikovitch TJ, Hounam J, Lopez M, Luu M, Fleshner P, Zaghayian K, et al. Association of wearable activity monitors with assessment of daily ambulation and length of stay among patients undergoing major surgery. JAMA Netw Open. 2019;2:e187673.
9. Cook DJ, Thompson JE, Prinsen SK, Dearani JA, Deschamps C. Functional recovery in the elderly after major surgery: assessment of mobility recovery using wireless technology. Ann Thorac Surg. 2013;96:1057-61.
10. Takahashi T, Kumanuma M, Jenkins S, Saitoh M, Morisawa T, Matsuda H. In-patient step count predicts re-hospitalization after cardiac surgery. J Cardiothorac Vasc Anesth. 2015;29:286-91.
11. Abeles A, Kwasnicki RM, Pettengell C, Murphy J, Darzi A. The relationship between physical activity and post-operative length of hospital stay: a systematic review. Int J Surg. 2017;44:295-302.
12. Hoyer EH, Friedman M, Lavezza A, Wagner-Kosmakos K, Lewis-Cherry R, Skohn J, et al. Promoting mobility and reducing length of stay in hospitalized geriatric medicine patients: a quality-improvement project. J Hosp Med. 2016;11:341-7.
13. Jeong IC, Healy R, Bao R, Xie W, Madeira T, Sussman M, et al. Assessment of patient ambulation profiles to predict hospital readmission, discharge location, and length of stay in a cardiac surgery progressive care unit. JAMA Netw Open. 2020;3:e201074.
14. Ustun TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. Developing the world health organization disability assessment schedule 2.0. Bull World Health Organ. 2010;88:815-23.
15. Ad N, Holmes SD, Shuman DJ, Pritchard G, Massimiano PS, Rongione AJ, et al. Potential impact of modifiable clinical variables on length of stay after first-time cardiac surgery. Ann Thorac Surg. 2015;100:2102-7; discussion 2107-8.
16. Stuebe J, Rydningward J, Lander H, Ng J, Xu X, Kaneko T, et al. A pragmatic preoperative prediction score for nonhome discharge after cardiac operations. Ann Thorac Surg. 2018;105:1384-91.
17. Kilic A, Magruder JT, Grimm JC, Duncan SP, Crawford T, Whitman GL, et al. Development and validation of a score to predict the risk of readmission after adult cardiac operations. Ann Thorac Surg. 2017;103:66-73.
18. Yousen WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-5.
19. Muschelli J. ROC and AUC with a binary predictor: a potentially misleading metric. J Classif. 2020;37:696-708.
20. Kamel HK, Igpal MA, Mogallapu R, Maas D, Hoffmann RG. Time to ambulation after hip fracture surgery: relation to hospitalization outcomes. J Gerontol A Biol Sci Med Sci. 2003;58:1042-5.
21. Smart DA, Dermody J, Coronado ME, Wilson M. Mobility programs for the hospitalized older adult: a scoping review. Gerontol Geriatr Med. 2018;4:2333721418808146.
22. Pashikanti L, Von Ah D. Impact of early mobilization protocol on the medical-surgical inpatient population: an integrated review of literature. Clin Nurse Spec. 2012;26:87-94. https://doi.org/10.1097/NUR.0b013e31824590e6
23. de Morton NA, Keating JL. JEFs K. Exercise for acutely hospitalised older medical patients. Cochrane Database Syst Rev. 2007;1:CD005955. https://doi.org/10.1002/14651858.CD005955.pub2
24. Kosse NM, Dutmier AL, Dassenbrock L, Bauer JM, Lamothe CJ. Effectiveness and feasibility of early physical rehabilitation programs for geriatric hospitalized patients: a systematic review. BMC Geriatr. 2013;13:107. https://doi.org/10.1186/1471-2318-13-107
25. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlak AJ, Esbrook CL, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373:1874-82. https://doi.org/10.1016/S0140-6736(09)60658-9
26. Kayambu G, Boots R, Paratz J. Physical therapy for the critically ill in the ICU: a systematic review and meta-analysis. Crit Care Med. 2013;41:1543-54. https://doi.org/10.1097/CCM.0b013e3182ea637
27. Young DL, Colantuoni E, Friedman LA, Seltzer J, Daley K, Ye B, et al. Prediction of disposition within 48 hours of hospital admission using patient mobility scores. J Hosp Med. 2020;15:540-3.
28. Hoyer EH, Young DL, Friedman LA, Brotman DJ, Klein LM, Friedman M, et al. Routine inpatient mobility assessment and hospital discharge planning. JAMA Intern Med. 2019;179:118-20.
29. Chawla H, Bulathsinghala C, Tejada JP, Wakefield D, ZuWallack R. Physical activity as a predictor of thirty-day hospital readmission after a discharge for a clinical exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:1203-9.
30. Trzeciak D, Hassett L, Schurr K, Chagpar S, Paul SS, Sherrington C. Validity of different activity monitors to count steps in an inpatient rehabilitation setting. Phys Ther. 2017;97:581-8.

Key Words: cardiac surgery, critical care, activity and mobility, accelerometers, physical therapy, older adults, functional status
APPENDIX 1. CARDIAC SURGERY WORKING GROUP

Glenn Whitman, MD, Kaushik Mandal, MD, Tim Madeira, CRNP, Michael C. Grant, MD, MSE, and Erik H. Hoyer, MD.

From the Departments of Surgery, Anesthesiology & Critical Care Medicine, and Physical Therapy, Johns Hopkins University School of Medicine, Baltimore, Md.

Present Address of Kaushik Mandal: Department of Surgery, Wayne State University School of Medicine, Detroit, Mich.

796 patients screened

Research staff or study equipment not available 339
Surgeon not participating 34
Patient decline 124
Change in schedule 31
Non-english speaking 29
Other 23

216 patients enrolled

No or ineligible surgery 4
Withdraw 4
Monitors not placed or monitor data not available 8
In-hospital death 7

193 patients included in the analysis

FIGURE E1. Patient flow diagram. The numbers of screened, enrolled, and analyzed patients are described.
### TABLE E1. Patient characteristics by duration of hospitalization

| Characteristic | Hospitalization ≤7 days | Hospitalization >7 days | P value |
|----------------|-------------------------|-------------------------|---------|
| Age, y, median (IQR) | 63 [56.5-69.5] | 70 [63-75] | <.001 |
| Male, no. (%) | 95 (84.82) | 63 (77.78) | .21 |
| White, no. (%) | 89 (79.46) | 58 (71.6) | .21 |
| Living with someone (spouse, family, other), no. (%) | 84 (76.36) | 62 (77.5) | .85 |
| Body mass index, kg/m², median (IQR) | 27.46 [24.74-31.88] | 28.75 [24.75-32.48] | .48 |
| IADL score, a median (IQR), (n = 189) | 14 [14-14] | 14 [14-14] | .26 |
| WHO-DAS score, b median (IQR), (n = 186) | 3 [1-6] | 5.5 [3-11.5] | <.001 |
| Logistic EuroSCORE | 2.22 [1.51-3.96] | 4.13 [2.63-8.1] | <.001 |
| Comorbidities | | | |
| Previous stroke or TIA, no. (%) | 8 (7.14) | 11 (13.58) | .14 |
| Depression, no. (%) | 6 (5.36) | 14 (17.28) | .01 |
| Hypertension, no. (%) | 92 (82.14) | 66 (81.48) | .91 |
| Congestive heart failure, no. (%) | 34 (30.36) | 38 (46.91) | .02 |
| Peripheral vascular disease, no. (%) | 11 (9.82) | 14 (17.28) | .13 |
| Diabetes, no. (%) | 38 (33.93) | 36 (44.44) | .14 |
| Previous tobacco use, no. (%) | 54 (48.21) | 55 (67.9) | .01 |
| COPD, no. (%) | 12 (10.71) | 14 (17.28) | .19 |
| Active alcohol and/or drug use, no. (%) | 19 (16.96) | 9 (11.11) | .25 |
| Medications | | | |
| Aspirin, no. (%) | 90 (80.36) | 61 (75.31) | .40 |
| Platelet aggregation inhibitor, no. (%) | 23 (20.54) | 17 (20.99) | .94 |
| Beta blocker, no. (%) | 77 (68.75) | 60 (74.07) | .42 |
| Calcium channel blocker, no. (%) | 36 (32.14) | 22 (27.16) | .46 |
| ACE inhibitor or ARB, no. (%) | 59 (52.68) | 35 (43.21) | .19 |
| Any anticoagulant (heparin, coumadin, other), no. (%) | 42 (37.5) | 39 (48.15) | .14 |
| Statin, no. (%) | 86 (76.79) | 62 (76.54) | .97 |
| Surgery type | | | |
| Isolated CAB, no. (%) | 70 (62.5) | 41 (50.62) | .01 |
| Isolated valve, no. (%) | 28 (25) | 21 (25.93) | |
| CAB + valve, no. (%) | 6 (5.36) | 16 (19.75) | |
| Other, no. (%) | 8 (7.14) | 3 (3.7) | |
| Duration of bypass, min, median (IQR) | 98 [73-124] | 118 [83-159] | .002 |
| Intraoperative pRBC transfusion, units, median (IQR) | 0 [0-0] | 0 [0-3] | <.001 |
| Duration of intubation, h, median (IQR) | 4.42 [3.33-6.13] | 7.5 [4.67-13] | <.001 |
| Intubation at 7 am on POD2, no. (%) | 1 (0.89) | 8 (9.88) | .005 |
| Duration of ICU stay, d, median (IQR) | 23.25 [20.3-41] | 71.5 [38-114.8] | <.001 |

**IQR**, Interquartile range; **IADL**, Instrumental Activities of Daily Living; **WHO-DAS**, World Health Organization Disability Assessment Schedule 2.0; **EuroSCORE**, European System for Cardiac Operative Risk Evaluation score; **TIA**, transient ischemic attack; **COPD**, chronic obstructive pulmonary disease; **ACE**, angiotensin-converting enzyme; **ARB**, angiotensin receptor blocker; **CAB**, coronary artery bypass; **pRBC**, packed red blood cells; **POD**, postoperative day; **ICU**, intensive care unit. aIADL scores range from 0 to 14, with a lower number indicating more difficulty with IADLs. bWHO-DAS 2.0 scores range from 0 to 48, with greater scores indicating greater impairment.
### TABLE E2. Patient characteristics by discharge location

| Characteristic                                   | Discharge to a nonhome location | Discharge home | P value |
|--------------------------------------------------|---------------------------------|----------------|---------|
| Age, y, median (IQR)                             | 74 (70.5-77)                    | 65 (57-71)     | .003    |
| Male, no. (%)                                    | 19 (79.2)                       | 139 (82.3)     | .71     |
| White, no. (%)                                   | 15 (62.5)                       | 132 (78.1)     | .09     |
| Living with someone (spouse, family, other), no. (%) | 16 (69.6)                      | 130 (77.8)     | .38     |
| Body mass index, kg/m², median (IQR)             | 28.2 (23.6-31.2)                | 28.3 (24.8-32.1)| .5      |
| IADL score,* median (IQR), (n = 189)             | 14 (14-14)                      | 14 (14-14)     | .33     |
| WHO-DAS score,† median (IQR), (n = 186)          | 5 (2.5-11)                      | 4 (2-8)        | .14     |
| Logistic EuroSCORE                               | 5.3 (2.5-12.6)                  | 2.8 (1.8-4.5)  | <.001   |
| Comorbidities                                    |                                 |                |         |
| Previous stroke or TIA, no. (%)                  | 5 (20.8)                        | 14 (8.3)       | .05     |
| Depression, no. (%)                              | 6 (25)                          | 14 (8.3)       |         |
| Hypertension, no. (%)                            | 23 (95.8)                       | 135 (79.9)     | .06     |
| Congestive heart failure, no. (%)                | 13 (54.2)                       | 59 (34.9)      | .07     |
| Peripheral vascular disease, no. (%)             | 3 (12.5)                        | 22 (13.0)      | .94     |
| Diabetes, no. (%)                                | 10 (41.7)                       | 64 (37.9)      | .72     |
| Previous tobacco use, no. (%)                    | 15 (62.5)                       | 94 (55.6)      | .52     |
| COPD, no. (%)                                    | 6 (25)                          | 20 (11.8)      | .08     |
| Active alcohol and/or drug use, no. (%)          | 5 (20.8)                        | 14 (8.3)       | .05     |
| **Medications**                                  |                                 |                |         |
| Aspirin, no. (%)                                 | 20 (83.3)                       | 131 (77.5)     | .52     |
| Platelet aggregation inhibitor, no. (%)          | 6 (25)                          | 34 (20.1)      | .58     |
| Beta blocker, no. (%)                            | 20 (83.3)                       | 117 (69.2)     | .15     |
| Calcium channel blocker, no. (%)                 | 7 (29.2)                        | 51 (30.2)      | .92     |
| ACE inhibitor or ARB, no. (%)                    | 10 (41.7)                       | 84 (49.7)      | .46     |
| Any anticoagulant (heparin, coumadin, other), no. (%) | 12 (50)                        | 69 (40.8)      | .39     |
| Statin, no. (%)                                  | 19 (79.2)                       | 129 (76.3)     | .76     |
| **Surgery type**                                 |                                 |                | .40     |
| Isolated CAB, no. (%)                            | 16 (66.7)                       | 95 (56.2)      | .52     |
| Isolated valve, no. (%)                          | 3 (12.5)                        | 46 (27.2)      |         |
| CAB + valve, no. (%)                             | 4 (16.7)                        | 18 (10.7)      | .006    |
| Other, no. (%)                                   | 1 (4.2)                         | 10 (5.9)       | .015    |
| Duration of bypass, median (IQR), (minutes)      | 118.5 [97.5-148]                | 118.5 [97.5-148]| .10    |
| Intraoperative pRBC transfusion, units, median (IQR) | 0.5 [0-3]                     | 0 (0-1)        | .007    |
| Duration of intubation, h, median (IQR)          | 11.6 [6.9-16.4]                 | 5 (3.5-7.5)    | .006    |
| Intubation at 7 AM on POD2, no. (%)              | 4 [16.67]                       | 5 (2.96)       | .015    |
| Duration of ICU stay, h, median (IQR)            | 71.4 [47.3-118]                 | 26.5 [21.3-64.8]| <.001  |

* IADL scores range from 0 to 14 with a lower number indicating more difficulty with IADLs. †WHO-DAS 2.0 scores range from 0 to 48, with greater scores indicating greater impairment.

IQR, Interquartile range; IADL, Instrumental Activities of Daily Living; WHO-DAS, World Health Organization Disability Assessment Schedule 2.0; EuroSCORE, European System for Cardiac Operative Risk Evaluation score; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAB, coronary artery bypass; pRBC, packed red blood cells; POD, postoperative day; ICU, intensive care unit.
### TABLE E3. Patient characteristics by 30-day readmission

| Characteristic                          | No readmission N = 154 | Readmission N = 34 | P value |
|-----------------------------------------|------------------------|--------------------|---------|
| Age, y, median (IQR)                    | 65.5 (57-72)           | 69.5 (61-75)       | .51     |
| Male, no. (%)                           | 132 (85.7)             | 21 (61.8)          | .001    |
| White, no. (%)                          | 119 (77.3)             | 23 (67.7)          | .23     |
| Living with someone (spouse, family, other), no. (%) | 113 (74.3)             | 29 (87.9)          | .1      |
| Body mass index, kg/m², median (IQR)    | 28.3 (24.8-32.1)       | 27.9 (23.9-31.8)   | .04     |
| IADL score,* median (IQR), (n = 189)    | 14 (14-14)             | 14 (13-14)         | <.001   |
| WHO-DAS score, y median (IQR), (n = 186) | 4 (1-7)                | 8 (2-14)           | <.001   |
| Logistic EuroSCORE                       | 2.785 (1.87-4.4)       | 4.185 (1.91-11.53) | <.001   |

### Comorbidities

| Comorbidity                              | No readmission N = 154 | Readmission N = 34 | P value |
|------------------------------------------|------------------------|--------------------|---------|
| Previous stroke or TIA, no. (%)          | 15 (9.74)              | 3 (8.82)           | .87     |
| Depression, no. (%)                      | 15 (9.74)              | 4 (11.76)          | .72     |
| Hypertension, no. (%)                    | 126 (81.82)            | 27 (79.41)         | .74     |
| Congestive heart failure, no. (%)        | 50 (32.47)             | 19 (55.88)         | .01     |
| Peripheral vascular disease, no. (%)     | 21 (13.64)             | 4 (11.76)          | .77     |
| Diabetes, no. (%)                        | 56 (36.36)             | 16 (47.06)         | .25     |
| Previous tobacco use, no. (%)            | 83 (53.9)              | 22 (64.71)         | .25     |
| COPD, no. (%)                            | 16 (10.39)             | 8 (23.53)          | .04     |
| Active alcohol and/or drug use, no. (%)  | 24 (15.58)             | 3 (8.82)           | .31     |

### Medications

| Medication                              | No readmission N = 154 | Readmission N = 34 | P value |
|-----------------------------------------|------------------------|--------------------|---------|
| Aspirin, no. (%)                        | 116 (75.32)            | 30 (88.24)         | .10     |
| Platelet aggregation inhibitor, no. (%) | 30 (19.48)             | 10 (29.41)         | .20     |
| Beta blocker, no. (%)                   | 108 (70.13)            | 25 (73.53)         | .69     |
| Calcium channel blocker, no. (%)        | 47 (30.52)             | 9 (26.47)          | .64     |
| ACE inhibitor or ARB, no. (%)           | 80 (51.95)             | 12 (35.29)         | .08     |
| Any anticoagulant (heparin, coumadin, other), no. (%) | 58 (37.66)             | 20 (58.82)         | .02     |
| Statin, no. (%)                         | 115 (74.68)            | 28 (82.35)         | .34     |

### Surgery type

| Type                                    | No readmission N = 154 | Readmission N = 34 | P value |
|-----------------------------------------|------------------------|--------------------|---------|
| Isolated CAB, no. (%)                   | 88 (57.14)             | 20 (58.82)         | .76     |
| Isolated valve, no. (%)                 | 42 (27.27)             | 7 (20.59)          |         |
| CAB + valve, no. (%)                    | 16 (10.39)             | 4 (11.76)          |         |
| Other, no. (%)                          | 8 (5.19)               | 3 (8.82)           |         |
| Duration of bypass, min, median (IQR)   | 104 (78-133)           | 113 (69-156)       | .58     |

### Intraoperative pRBC transfusion, units, median (IQR)

| Duration of intubation, h, median (IQR) | 5 (3.5-8.25) | 7.13 (4.17-11) | .19     |
| Intubation at 7 am on POD2, no. (%)     | 6 (3.9)       | 3 (8.82)       | .22     |

### Duration of ICU stay, h, median (IQR)

| Duration of ICU stay, h, median (IQR)   | 27 (21.2-62.8) | 69 (26.8-114.8) | <.001   |

IQR, Interquartile range; IADL, Instrumental Activities of Daily Living; WHO-DAS, World Health Organization Disability Assessment Schedule 2.0; EuroSCORE, European System for Cardiac Operative Risk Evaluation score; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease, ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAB, coronary artery bypass; pRBC, packed red blood cells; POD, postoperative day; ICU, intensive care unit. *IADL scores range from 0 to 14 with a lower number indicating more difficulty with IADLs. WHO-DAS 2.0 scores range from 0 to 48, with greater scores indicating greater impairment.
### TABLE E4. Comparing C-statistics using different approaches

| Approaches to calculate | C-statistic | ActiGraph | StepWatch Ambulation | Fitbit | Johns Hopkins-Highest Level of Mobility Scale |
|-------------------------|-------------|-----------|----------------------|--------|----------------------------------------------|
| **Duration of hospitalization** |             |           |                      |        |                                              |
| >7 days                 | Method 1*   | 0.69      | 0.74                 | 0.53   | 0.59                                         |
|                        | Method 2†   | 0.7       | 0.75                 | 0.59   | 0.72                                         |
| **Discharge to a nonhome location** |             |           |                      |        |                                              |
|                        | Method 1*   | 0.78      | 0.76                 | 0.595  | 0.73                                         |
|                        | Method 2†   | 0.79      | 0.78                 | 0.69   | 0.8                                          |
| **30-d readmission**   | Method 1*   | 0.63      | 0.71                 | 0.47   | 0.51                                         |
|                        | Method 2†   | 0.64      | 0.73                 | 0.54   | 0.63                                         |

*Method 1 is calculated using the mROC package in R to account for the nonstandard relationship between mobility and the outcome of interest (ie, the outcome of interest is more likely with decreasing mobility). †Method 2 is calculated using the fbroc package in R to account for categorical and zero-inflated measurements.